Dendreon Corp fka DNDNQ

[rancherho]

The current issue of the Journal of Clinical Oncology raises an interesting issue regarding the standard use of X-rays and radio-labeled markers to identify bone mets in advanced prostate cancer instead of MRIs, and reported that “MRIs identified metastases in seven (30%) of 23 patients considered negative and eight (47%) of 17 patients considered equivocal by other strategies”. Journal of Clinical Oncology, Vol 25, No 22 (August 1), 2007: pp. 3281-3287 http://jco.ascopubs.org/cgi/content/abstract/25/22/3281
Considering that the number of bone mets is considered an important and heavily weighted prognostic factor in the Halabi nomogram and in measuring Time to Progression changes from the time of randomization, any AIPC clinical trial measuring TTP in AIPC without using MRI’s can’t be very accurate. Surprising, considering how long MRI’s have been around.